NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/14/2026
Back to search
Official data from USPTO
AMOLYT PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
AMOLYT PHARMA
ST13
US500000079286937Class
42
Filing
79286937
Registration
6324872
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
05/15/2026
Trademark type
Word
Nice classes
42
Filing date
04/27/2020
Registration date
04/20/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/20/2021
Last transaction
05/15/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
34
Owner location
FR
Examiner
FITZSIMONS, MICHAEL R
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
A. P. (pessoa física)
Representatives
Cara M. Kearney AstraZeneca Pharmaceuticals LP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development services for pharmaceutical preparations
Publications
History of USPTO decisions and trademark events.
34 publications found
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/20/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/01/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/01/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/01/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/12/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/07/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/11/2023
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
08/14/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/29/2021
FIMP
FINAL DISPOSITION PROCESSED
07/29/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/20/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
04/20/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/02/2021
PUBO
PUBLISHED FOR OPPOSITION
02/02/2021
GPNX
NOTIFICATION PROCESSED BY IB
01/30/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/13/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/13/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/13/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/28/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/28/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/28/2020
ALIE
ASSIGNED TO LIE
12/28/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/28/2020
RFNT
REFUSAL PROCESSED BY IB
09/27/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/05/2020
RFRR
REFUSAL PROCESSED BY MPU
08/27/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/23/2020
CNRT
NON-FINAL ACTION WRITTEN
07/22/2020
DOCK
ASSIGNED TO EXAMINER
07/20/2020
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
07/16/2020
MAFR
APPLICATION FILING RECEIPT MAILED
06/09/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/05/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/04/2020
Continuous trademark protection
Get notified about every new filing that threatens AMOLYT PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.